IMUX / Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2022 Results - Earnings Call Transcript

Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protec more_horizontal

Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (I more_horizontal

Shares in Immunic Therapeutics Inc. soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER tr more_horizontal

Immunic Inc (NASDAQ:IMUX) said it has completed the enrollment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patien more_horizontal

Immunic, Inc. said that at the end of its second quarter to June 30, 2023, it had cash, cash equivalents and investments of $77.3 million with which more_horizontal

New York-based biotechnology company Immunic Inc (NASDAQ:IMUX) has one or more potential blockbusters in its clinical pipeline. The firm's promising l more_horizontal

7:55am: Deal or no deal? Wall Street is likely to open in the green as traders return from the Memorial Day long weekend to news that US President Jo more_horizontal

NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, more_horizontal